The objective of this study was to document the convulsant properties of thiocolchicoside in rats, and to characterise the electroclinical pattern of epileptic seizures. Experiments were carried out in three groups of male Wistar rats: in group A, thiocolchicoside was applied topically to the pia, or given by microinjection to the cerebral cortex (2 µg/µl); in group B, the drug was administered parenterally (6 mg/kg) to rats with minimal lesions of the dura and arachnoid membranes; in group C, thiocolchicoside was administered parenterally (up to 12 mg/kg) to intact rats. In all animals, electroclinical activity was continuously monitored for at least 3 hours after thiocolchicoside injection or application. In group A, electrographic and behavioural activity of focal motor seizures occurred in 100% of animals, developing into a focal status epilepticus; in group B, a multifocal epileptic pattern with secondary generalisation, clinically characterised by clonic or tonic-clonic seizures occurred in 100% of animals, until a secondarily generalised convulsive status epilepticus; in group C, none of animals showed either electrographic or behavioural seizure activity. Our study documents that thiocolchicoside has a powerful convulsant activity in the rat, perhaps due to an antagonistic interaction of the compound with a cortical subtype of the GABA A receptor.
INTRODUCTION
Thiocolchicoside is a semi-synthetic derivative of a naturally occurring colchicoside, a colchicine analogue, extensively used clinically in some countries as central acting muscle-relaxant, anti-inflammatory and analgesic ( Fig. 1) 1 . Colchicine may induce experimental epileptic foci in animals (mice, rabbits and rats) 2 , and its intracranial administration causes generalised convulsions and death 3 . Our preliminary experimental findings, presented previously as an abstract 4 , and our recent clinical data 5 indicate that thiocolchicoside also has powerful convulsant activity in animals and in humans; particularly, in neurological patients with disruption of their blood-brain barrier (BBB) and in patients with history of epilepsy 5 . In this paper, we document the occurrence of focal and secondarily generalised convulsive status epilepticus in the rat following the administration of thiocochicoside. In order to induce focal status epilepticus, this drug was applied topically to the pia or given by microinjection to the cerebral cortex. To induce a secondarily generalised status epilepticus, it was administered parenterally to rats with minimal lesions of the dura and arachnoid membranes.
METHOD
Studies were performed under a protocol approved by the Institutional Animal Care Committee. Male rats, Wistar Morini strain, weighing 270-350 g (3-4 months of age), fasting for 12 hours before the experiments, and kept at a room temperature for 22 • C, were anaesthetised with ether or ketamine hydrochloride (about 50 mg/kg, intraperitoneally), the head mounted in a stereotactic apparatus. Animals were randomly divided into three groups (groups A, B and C). The rats of group A were further divided into two subgroups: in the first, after ketamine anaesthesia, the cerebral cortex was exposed by craniotomy, the dura was removed and electrocorticographic (ECoG) patterns recorded bipolarly by six silver-ball electrodes applied to the pia in bilateral symmetrical position (the reference electrode was a screw placed on the nasal bone). Focal epileptic seizures were induced in the exposed cortex (right or left) by application of a small piece of Spongostan (2 mm × 2 mm), a sponge of fibrin soaked in a 2 mg/ml isotonic sodium chloride solution of thiocolchicoside (15 animals). In the second subgroup, focal seizures were induced by one intracortical microinjection of thiocolchicoside dissolved in saline (the injection volume used was 1 µl and the total amount of thiocolchicoside applied was 2 µg), near the recording electrodes (10 animals). In this latter subgroup, each animal underwent a tracheotomy under ether anaesthesia, and was then immobilised with gallamine and artificially ventilated. Novocaine infiltration of all warmed edges and pressure points was carefully carried out to minimise possible source of pain.
In group B, after ketamine anaesthesia, thiocolchicoside dissolved in saline was administered either into the peritoneum (i.p.), or intramuscularly (i.m.) (6 mg/kg) to rats with minimal lesions of the dura and arachnoid membranes. The lesions of these membranes occurred during the insertion of the screw electrodes into the skull, or during craniotomy. In particular, the lesions made during the insertion of the screw electrodes were four, in symmetrical positions in the area of the frontoparietal cortex bilaterally. The extent of the lesions induced by screw electrodes or craniotomy was about 0.1 mm × 0.1 mm and 2 mm × 2 mm, respectively. In preliminary experiments, different amounts of thiocolchicoside were injected i.p. or i.m. in rats of the same age and weight in order to establish the necessary dose of the drug needed to induce constant and reliable electroclinical responses. Similarly, the extent of the lesions of dura and arachnoid membranes needed to obtain constant and reliable seizure activity was established in preliminary experiments. The surface electroencephalogram (EEG) was recorded from the cortical convexity either by means of six screw electrodes inserted into the skull in bilateral symmetrical positions (the reference electrode placed on the nasal bone) (15 animals) or, when a wide craniotomy was performed, by using six ball electrodes applied to the pial surface (the reference electrode was a screw electrode placed on the nasal bone) (10 animals). In some cases bipolar concentric electrodes were stereotaxically implanted into subcortical structures according to the atlas of Paxinos and Watson 6 . The following structures were explored: left basolateral amygdaloid nucleus anterior (BLA) (referred to bregma: 2.8 mm posterior, 8.5 mm ventral, 5.0 mm lateral to the midline) (five animals) and gigantocellular proper mesencephalic reticular formation (MRF-Gi) (referred to bregma: 10.8 mm posterior, 9.5 mm lateral to the midline, 10 mm ventral) (five animals).
In group C, thiocolchicoside dissolved in saline was administered i.p. or i.m. to intact rats, at doses of 6 mg/kg (five animals), 8 mg/kg (five animals) and 12 mg/kg (five animals). The surface EEG was recorded by means of six subcutaneous needle electrodes inserted in bilateral symmetrical position (the reference electrode was fixed on the pinna).
In all animals the exposed cortex was covered with warmed paraffin oil at 37 • C. Body temperature was maintained between 36.5 and 37.5 • C with a heating pad. Both depth and surface electrodes were connected to an EEG recording apparatus (OTE Biomedica). The electrocardiogram was routinely monitored. All animals were continuously monitored for at least 3 hours after the thiocolchicoside injection or application. At least 10 minutes of basal ECoG or EEG recording was made in each animal. The position of the depth electrodes was checked. Data given are mean ± standard deviation.
RESULTS
In group A, treated with focal cortical thiocolchicoside, electrographic and behavioural seizure activity occurred in 100% of animals. The latency to focal spike activity was 3 ± 2 minutes following topical application of the drug on the pial surface, and 2.0 ± 1 minute following one intracortical microinjection. The frequency of spikes was 48 ± 20 minutes. After about 60 minutes, spikes and polyspikes, intermingled with both bursts of focal recruiting discharges of 1.5-to 3-second duration and intermittent ictal focal seizures of several seconds duration occurred, accompanied by controlateral myoclonic jerks (Fig. 2) . The electrographic seizure activity was interrupted by a near complete depression of cortical activity on ECoG. This activity progressed into a focal status epilepticus and lasted for at least 3 hours.
In group B, treated with parenteral thiocolchicoside, a multifocal epileptic pattern with secondary generalisation, clinically characterised by clonic or tonic-clonic seizures occurred in 100% of animals. The latency to first spike activity and to the first secondarily generalised seizure until a convulsive status epilepticus developed was 3 ± 1 and 60 ± 10 minutes, respectively. After thiocolchicoside injection, the spikes rose from the opposite hemisphere in a completely asynchronous way for 2-4 minutes, since when a progressive and rapid temporal alliance between the epileptic activity of the two hemispheres was observed, giving origin to a pseudogeneralised pattern. The amplitude and frequency of spikes rapidly increasing, up to 0.6 mV and 50/minute, respectively. After about 1 hour, the epileptic potentials became subcontinuous and characterised by spike trains until ictal electroclinical generalised seizures mainly clonic or, occasionally tonic-clonic, which lasted 20-180 seconds (Fig. 3) . The interval of intermittent generalised seizure activity was 60 ± 20 minutes. This activity lasted for at least 3-5 hours, and resulted in death in about 5% of treated rats. Depth electrode recordings initially showed no involvement of the explored structures. With an 8-to 15-minute delay, as to the cortex, paroxysmal activity appeared also in subcortical structures, at first in BLA, then in MRF-Gi. At this time, a high degree of synchrony of spiking between the various structures was evident (Fig. 4) .
In group C, at the doses tested, none of animals showed either electrographic or behavioural seizure activity.
DISCUSSION
Thiocolchicoside, colchicoside and colchicine share the same benzo[α]heptalenic moiety, however, thiocolchicoside differs from colchicoside and colchicine by substitution of a methoxy group for a thiomethyl group on ring A (Fig. 1) 1 . Structural analysis of these compounds reveals the need for at least a single methoxy group on rings A and C for neurotoxicity of colchicine 2 . This drug, indeed, binds to tubulin and has been found to be a selective toxin for dentate granule cells in the hippocampus of rats 2 . The concomitance of a methoxy group on rings A and C, instead, does not seem necessary for the convulsant activity of colchicine 2 . Our data on the powerful convulsant activity of thiocolchicoside (lacking a methoxy group on ring A) agree with these findings.
Our study documents that thiocolchicoside given at doses of 6-12 mg/kg is unable to induce, in intact rats, any electrical or behavioural paroxysmal activity. However, when this compound is applied topically to the pia, given by microinjection to cerebral cortex, or administered parenterally at doses of 6 mg/kg to rats with minimal lesions of the dura and arachnoid membranes, it displays within a few minutes, a powerful convulsant activity.
The impermeability of the BBB to thiocolchicoside is likely related to the dose used since in preclinical studies 1 it was noted that in mice, at doses of 20 mg/kg of thiocolchicoside, some animals exhibited trembling and died 40 minutes after dosing. The relative impermeability of the BBB to therapeutic doses of thiocolchicoside may explain why the convulsant activity of this drug in humans so far has not been recognised, despite its extensive use in clinical practice for about 30 years 5 .
In our experiments, after topical microinjection, thiocolchicoside was able to induce focal cortical seizures in micromolar amounts and after a short latent period, while after its parenteral administration, cortical spikes occurred firstly before subcortical structures. These findings, in our opinion, strongly point to the forebrain, and more specifically the cortex, as the likely site where thiocolchicoside-induced seizures are initiated. The occurrence of the highest levels of specific thiocolchicoside binding in the deep layers of the frontal cortex of the rat fits this possibility 7 .
The mechanism of action of thiocolchicoside is only partially understood. Previous studies suggested that an agonistic interaction of thiocolchicoside with spinal-strychnine-sensitive glycine receptors could mediate its myorelaxant activity 8 ; such interaction, however, does not readily explain how it may induce seizures 5 .
Recent studies have, instead, demonstrated the presence of thiocolchicoside-specific binding sites in the rat cerebral cortex and in spinal cord-brainstem 9 , with a pharmacological profile indicating a preferential interaction of this compound with a cortical subtype of the GABA A receptor 9 . This peculiar interaction is suggested both by the different affinities for the GABA A receptor agonists and antagonists, and by the finding that neurosteroids modulate the binding in cortical but not in spinal cord-brainstem synaptic membranes 9 . In particular, at cortical level, thiocolchicoside seems to recognise a subpopulation of GABA A receptors, expressing low-affinity binding sites for GABA 9 . Since the low-affinity recognition site seems to be an antagonistic-preferring site 7 , this finding may readily explain both the electrophysiological results reported in this study and the powerful convulsant activity of thiocolchicoside noticed in humans 5 .
Another interesting finding concerns the potency of strychnine in inhibiting thiocolchicoside binding, particularly in the cerebral cortex 9 , suggesting a probable interaction of both compounds at the same binding sites 9 at cortical level. Strychnine, it has recently been shown, may interact in the brain, at submicromolar doses, with strychnine-sensitive glycine receptors, GABA A receptors, as well as nicotinic acetylcholine receptors [8] [9] [10] , which are homologous members of a receptor superfamily 11, 12 .
Like strychnine, thiocolchicoside has been shown to interact with GABA A receptors and strychnine-sensitive glycine receptors 8, 9 . These latter receptors are mainly represented in the spinal cord and brainstem 13 , and might be involved in the myorelaxant activity of thiocolchicoside 8 . GABA A receptors, instead, are mainly represented in the cerebral cortex 14, 15 , and may be involved both in the convulsant activity of thiocolchicoside, and in spiking produced by strychnine in the cortex 16 . In particular, the convulsant activity of thiocolchicoside is likely to involve an overcoming effect of thiocolchicoside antagonism at a subset of GABA A receptors, on thiocolchicoside inhibitory effects of allosteric activation of strychnine-sensitive glycine receptors. The prevalence of GABA A receptors in the cerebral cortex, with respect to strychninesensitive glycine receptors, fits this possibility [13] [14] [15] .
According to Engel 17 , in epilepsy research the thiocolchicoside model would be classified with the group of 'acute experimentally induced seizure models', which would be equivalent to reactive seizures in humans, or with the group of animal models of epileptic seizures in nonepileptic animals reported by Löscher in a recent review 18 . The electroclinical pattern was consistent with an acute focal and secondarily generalised convulsive status epilepticus. In this model, the occurrence of a minimally disrupted BBB parallels a condition that can be found frequently in clinical practice (e.g. after head trauma), in which it has been shown that thiocolchicoside may induce epileptic seizures in humans, at very low doses 5 . In comparison with similar models characterised in far greater detail (e.g. those obtainable with bicuculline or strychnine or kainate) 17, 18 , the thiocolchicoside model shows the same reproducibility and consistency and a peculiar mechanism of action (i.e. an antagonistic interaction with a subset of GABA A receptors, and an agonistic interaction with strychnine-sensitive glycine receptors) 7, 9 . This model could have utility in studies of the functional anatomy, neural networks and neurochemical mechanisms involved in epilepsy and epileptic seizures.
CONCLUSIONS
Our experimental data document that thiocolchicoside has a powerful convulsant activity in the rat. The mechanism by which this drug produces focal and secondarily generalised convulsive status epilepticus deserves further investigation. Moreover, our findings confirm the data obtained in humans indicating that the convulsant activity of thiocolchicoside occurs mainly when there are minimal lesions of the dura and arachnoid membranes.
